Different abnormalities of mismatch negativity in schizophrenia and depression as assessed with...

Mismatch negativity (MMN) is widely considered a candidate diagnostic biomarker for schizophrenia (SCZ). Although blunted MMN responses have been reliably observed in psychosis, the evidence for MMN deficits in other disorders, such as major depressive disorder (MDD), is mixed. This study explores whether MMN alterations in amplitude or latency are unique to SCZ or extend to non-psychotic MDD patients. Seventeen patients diagnosed with a first MDD episode, 18 with recurrent MDD, 17 with first episode of SCZ spectrum disorder, and 18 with chronic SCZ, along with two groups of age- and sex-matched neurotypical controls (NC, 17 and 18), participated in a passive auditory MMN task during magnetoencephalography (MEG) recording. We examined the magnetic MMN (mMMN) amplitude and latency, exploring potential links between observed MMN alterations and psychotropic medication treatments. The mMMN amplitudes were significantly attenuated in SCZ compared to NC. Although, on average, mMMN amplitudes also appeared to be small in MDD, there was no significant difference between MDD and SCZ or NC. Notably, MDD patients had longer mMMN latencies compared to SCZ and NC, especially those with recurrent MDD. These results remained consistent after controlling for mood stabilizers, antidepressants, or benzodiazepines. These findings show that mMMN amplitude reductions may be more pronounced in psychotic disorders than in depressive disorders, whereas abnormal mMMN latencies may be more specific to MDD, suggesting differential mMMN alterations in SCZ and MDD. Caution is advised regarding mMMN amplitude as a diagnostic biomarker for SCZ, as small reductions also occur in MDD.